There were no differences in overall survival time, progression-free survival time, and quality of life between elderly and/or frail patients with newly diagnosed glioblastoma multiforme receiving 2 radiotherapy regimens, a new study published online ahead of print in the Journal of Clinical Oncology has shown.1
Because the optimal radiotherapy regimen for elderly and/or frail patients has not been established, researchers sought to compare 2 radiotherapy regimens on the outcome of these patients.
Researchers enrolled 98 patients and randomly assigned them 1:1 to receive short-course radiotherapy (25 Gy in 5 daily fractions over 1 week) or commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks).
Results showed that the short-course radiotherapy was noninferior to commonly used radiotherapy. Median overall survival time was 7.9 months (95% CI: 6.3-9.6) with short-course radiotherapy and 6.4 months (95% CI: 5.1-7.6) with commonly used radiotherapy (P=0.988). Median progression-free survival time was 4.2 months (95% CI: 2.5-5.9) and 4.2 months (95% CI: 2.6-5.7), respectively (P=0.716).
RELATED: Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma
Researchers found that quality of life did not differ between treatment arms both at 4 and 8 weeks after treatment.
“In view of the reduced treatment time, the short 1-week radiotherapy regimen may be recommended as a treatment option for elderly and/or frail patients with newly diagnosed glioblastoma,” the authors concluded.
- Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme [published online ahead of print September 21, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.62.6606.